ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0740

Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica

Patricia Harkins1, Sharon Cowley2, seoidin McKittrick3, Robert Harrington4, David Kane5 and Richard Conway6, 1Trinity College Dublin, Dublin 8, Dublin, Ireland, 2Tallaght University Hospital, Dublin, Dublin, Dublin, Ireland, 3University of Limerick, Limerick, Ireland, 4St. James's Hospital, Dublin, Dublin, Ireland, 5Tallaght University Hospital & Trinity College Dublin, D24, Ireland, 6Trinity College Dublin, Dublin, Ireland

Meeting: ACR Convergence 2024

Keywords: Aging, grip strength, osteoporosis, Polymyalgia Rheumatica (PMR)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Polymyalgia Rheumatica (PMR) is the most common inflammatory rheumatic disease in older adults, and aging has been postulated to be central to its pathophysiology. The objective of this study was to assess the prevalence of the physical phenotypes of aging in those newly diagnosed with isolated PMR.

Methods: Patients were recruited over a 12 month period from a multi-centre fast track PMR clinic. Frailty status was assessed using the SHARE-FI tool. Cognitive status was assessed using the Montreal cognitive assessment tool (MOCA), with a cut-off of < 26 used to define cognitive impairment. Bone mineral density was assessed using DEXA, whilst sarcopenia was assessed using the SARC-F questionnaire. Mood, anxiety, fatigue and pain were assessed using the PHQ-9. GAD-7, FACIT-F and pVAS screening tools respectively. Disease activity was assessed using the PMR-activity score (PMR-AS).
Normally distributed continuous variables are expressed as means with standard deviations (SD). Continuous variables are compared using the independent t-test. Categorical variables are summarised as frequency and percentage (%) and compared using chi-square test. The association between continuous variables and categorical variables is assessed using the Kruskal-Wallis test. The statistical analysis was performed using STATA MP Version 18. P values < 0.05 are considered statistically significant.

Results: 79 newly diagnosed patients (48% (n=38) female) were recruited. At baseline 40.5% (n=32) patients were frail, 27.8% (n=22) were pre-frail, and 31.6% (n=25) were robust. Increased frailty status was associated with a a significant difference in mean FACIT-F (p=0.00), pVAS (0.028), PHQ-9 (0.00) and GAD-7 (0.014) scores. 74.4% of patients had evidence of cognitive impairment at baseline. There was no significant difference between age, sex, BMI or disease activity across the different frailty or cognitive categories. 23% (n=18) had evidence of sarcopenia. 43 patients had baseline DEXA scans, with 21.4% (n=9) demonstrating osteoporosis, and a further 30% (n=13) osteopenia.

Conclusion: This study provides preliminary evidence for an accelerated physical aging phenotype in PMR. Further studies are needed to explore the role of inflammaging and immunosenescence in the pathophysiology of PMR.

Supporting image 1

Table 1: Breakdown of each aging physical phenotype in those with newly diagnosed PMR.


Disclosures: P. Harkins: Janssen Pharmaceuticals, 5, Novartis Pharmaceuticals, 5; S. Cowley: AbbVie/Abbott, 12, Support to attend conference, Novartis, 5, 12, Support to attend conference; s. McKittrick: None; R. Harrington: None; D. Kane: None; R. Conway: AbbVie/Abbott, 5, 6, Celltrion, 5, Fresenius Kabi, 6, Galapagos, 6, Janssen, 5, 6, Novartis, 5, 6, UCB, 6, Viatris, 6.

To cite this abstract in AMA style:

Harkins P, Cowley S, McKittrick s, Harrington R, Kane D, Conway R. Evaluation of an Accelerated Physical Aging Phenotype in Newly Diagnosed Patients with Polymyalgia Rheumatica [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-an-accelerated-physical-aging-phenotype-in-newly-diagnosed-patients-with-polymyalgia-rheumatica/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-an-accelerated-physical-aging-phenotype-in-newly-diagnosed-patients-with-polymyalgia-rheumatica/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology